TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24938081

Group type: EXPERIMENTAL
Intervention: Behavioral activation treatment for depression (10 sessions)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Supportive counseling (10 sessions)
Number of subjects: 60
Study: 23031319

Group type: EXPERIMENTAL
Intervention: Experimental homologous (07 V063) inactivated vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Commercial attenuated vaccines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental heterologous (LV) inactivated vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Commercial inactivated vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental homologous (08 V194) inactivated vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Commercial attenuated vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental heterologous (07 V063 and LV) inactivated vaccines
Number of subjects: 0
Study: 20397881

Group type: EXPERIMENTAL
Intervention: Smoking Prevention Interactive Experience (ASPIRE) intervention
Number of subjects: 1574
Study: 18500375

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim 18 mg
Number of subjects: 61

Group type: COMPARATOR
Intervention: Filgrastim (10 microg/kg)
Number of subjects: 61
Study: 15689862

Group type: EXPERIMENTAL
Intervention: Phantom bioabsorbable polymer interference screw
Number of subjects: 97

Group type: COMPARATOR
Intervention: Titanium metal interference screw
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 97
Study: 12067858

Group type: EXPERIMENTAL
Intervention: Hydrocortisone infusion
Number of subjects: 7
Study: 10078857

Group type: EXPERIMENTAL
Intervention: Walking program
Number of subjects: 85

Group type: COMPARATOR
Intervention: No-exercise group
Number of subjects: 85
Study: 7728788

Group type: EXPERIMENTAL
Intervention: Supraventricular tachycardia
Number of subjects: 897

Group type: COMPARATOR
Intervention: No supraventricular tachycardia
Number of subjects: 897

Group type: EXPERIMENTAL
Intervention: Supraventricular tachycardia, atrial fibrillation, advanced atrioventricular block, sinoatrial block
Number of subjects: 897
Study: 2073205

Group type: EXPERIMENTAL
Intervention: 2% minoxidil solution
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo vehicle
Number of subjects: 169
Study: 427007

Group type: EXPERIMENTAL
Intervention: Conventional oxprenolol tablets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Slow-release oxprenolol tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (nonfasted condition)
Number of subjects: 0
Study: 31432744

Group type: EXPERIMENTAL
Intervention: Christianen et al. model for predicting physician-rated dysphagia
Number of subjects: 588
Study: 28410791

Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg twice per day plus esomeprazole 20 mg once per day
Number of subjects: 514

Group type: COMPARATOR
Intervention: Naproxen 500 mg twice per day plus esomeprazole 20 mg once per day
Number of subjects: 514
Study: 26267726

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 367
Study: 23575220

Group type: EXPERIMENTAL
Intervention: Griseofulvin 15 mg/kg/day
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Griseofulvin 25 mg/kg/day
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Fluconazole 4 mg/kg/day
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Fluconazole 6 mg/kg/day
Number of subjects: 113
Study: 21242997

Group type: EXPERIMENTAL
Intervention: Tilt angles of 10° increments (0° to 50°) in a manual wheelchair
Number of subjects: 18
Study: 19106674

Group type: EXPERIMENTAL
Intervention: Laparoscopic sigmoid resection (LSR)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Open sigmoid resection (OSR)
Number of subjects: 104
Study: 17584749

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural group treatment (CBT), n = 19
Number of subjects: 39

Group type: COMPARATOR
Intervention: Waiting-list control, n = 20
Number of subjects: 39
Study: 15177794

Group type: EXPERIMENTAL
Intervention: Phantom hand representing the unseen hand holding a tactile stimulus of same or different size
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Virtual reality box illusions
Number of subjects: 0
Study: 12269650

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide aqueous (TAA)
Number of subjects: 95
Study: 9696254

Group type: EXPERIMENTAL
Intervention: Gingivitis scores
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plaque scores
Number of subjects: 0
Study: 8606536

Group type: EXPERIMENTAL
Intervention: Extended-release felodipine (10 mg once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Slow-release nifedipine (20 mg twice daily)
Number of subjects: 0
Study: 2672484

Group type: EXPERIMENTAL
Intervention: Lixiscope
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional X-ray
Number of subjects: 24
Study: 361349

Group type: EXPERIMENTAL
Intervention: Glucamethacin (420 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Indomethacin (100 mg/day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Glucamethacin (420 mg/day) in patients with gastro-duodenal pathology
Number of subjects: 100
Study: 31444185

Group type: EXPERIMENTAL
Intervention: Online intervention to enhance problem solving ability
Number of subjects: 25

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 25
Study: 27884497

Group type: EXPERIMENTAL
Intervention: Rotator cuff muscle strengthening exercises
Number of subjects: 42

Group type: COMPARATOR
Intervention: TENS and joint mobilization
Number of subjects: 42
Study: 26498699

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray (FFNS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mometasone furoate nasal spray (MFNS)
Number of subjects: 40
Study: 25079375

Group type: EXPERIMENTAL
Intervention: Topical application of a mixture of two dimeticones of low viscosity (NYDA)
Number of subjects: 47

Group type: COMPARATOR
Intervention: 0.05% solution of KMnO4
Number of subjects: 47
Study: 23088223

Group type: EXPERIMENTAL
Intervention: FRAX® tool without bone mineral density (BMD)
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: FRAX® tool with T-score of femoral neck (FN)
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: FRAX® tool for hip fracture without BMD
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: FRAX® tool for hip fracture with BMD
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Model with BMD alone
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Model with age alone
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: ObsFx/ExpFx ratio for major fracture
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: ObsFx/ExpFx ratio for hip fracture without BMD
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: ObsFx/ExpFx ratio with BMD for major fracture
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: ObsFx/ExpFx ratio with BMD for hip fracture
Number of subjects: 770
Study: 19744889

Group type: EXPERIMENTAL
Intervention: Consultation training in patient‐centred counselling and cardiovascular prevention
Number of subjects: 19
Study: 18036292

Group type: EXPERIMENTAL
Intervention: Shenfu injection (20 ml/L added to blood containing cardioplegic liquid)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (4:1 blood containing cardioplegic liquid)
Number of subjects: 40
Study: 14972481

Group type: EXPERIMENTAL
Intervention: Positive biopsy group
Number of subjects: 9575

Group type: EXPERIMENTAL
Intervention: Negative biopsy group
Number of subjects: 9575

Group type: EXPERIMENTAL
Intervention: No biopsy indication group
Number of subjects: 9575
Study: 11564197

Group type: EXPERIMENTAL
Intervention: GP tutor visit
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Mailing
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control
Number of subjects: 112
Study: 9627585

Group type: EXPERIMENTAL
Intervention: Fentanyl (3 micrograms/kg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 8147361

Group type: EXPERIMENTAL
Intervention: famotidine 40 mg
Number of subjects: 594

Group type: COMPARATOR
Intervention: ranitidine 300 mg
Number of subjects: 594
Study: 3076792

Group type: EXPERIMENTAL
Intervention: Nebuhaler (10 mg terbutaline sulphate four times daily)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Jet nebulizer (10 mg terbutaline sulphate four times daily)
Number of subjects: 13
Study: 29515037

Group type: EXPERIMENTAL
Intervention: CYT107 (recombinant human IL-7)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 28835268

Group type: EXPERIMENTAL
Intervention: Preoperative antibiotic prophylaxis (2000 mg of first-generation cephalosporin delivered intravenously)
Number of subjects: 454

Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 454
Study: 26339178

Group type: EXPERIMENTAL
Intervention: Opposite Side (OS) position for changing compression
Number of subjects: 64

Group type: COMPARATOR
Intervention: Same Side (SS) position for changing compression
Number of subjects: 64
Study: 24035939

Group type: EXPERIMENTAL
Intervention: Garlic tablets at 300 mg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Garlic tablets at 600 mg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Garlic tablets at 900 mg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Garlic tablets at 1200 mg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Garlic tablets at 1500 mg
Number of subjects: 210

Group type: COMPARATOR
Intervention: Atenolol (control)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 210
Study: 21242022

Group type: EXPERIMENTAL
Intervention: Pharmacological treatment with exercise programme
Number of subjects: 43

Group type: COMPARATOR
Intervention: Pharmacological treatment only
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study: 18922829

Group type: EXPERIMENTAL
Intervention: Lenalidomide and dexamethasone (LD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo and dexamethasone (PD)
Number of subjects: 0
Study: 17029128

Group type: EXPERIMENTAL
Intervention: Pyridoxine
Number of subjects: 24
Study: 12711266

Group type: EXPERIMENTAL
Intervention: Group cognitive treatment for pathological gambling
Number of subjects: 58

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 58
Study: 16138577

Group type: EXPERIMENTAL
Intervention: Clinical treatment for patients with aberrant sperm nuclear proteins (n=30)
Number of subjects: 199
Study: 10077290

Group type: EXPERIMENTAL
Intervention: Manual-assisted cognitive-behaviour therapy (MACT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 34
Study: 7740627

Group type: EXPERIMENTAL
Intervention: REC diet (low-fat, 28% of energy, high-fibre, 3.3 g/MJ)
Number of subjects: 21
Study: 2258871

Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg twice daily
Number of subjects: 31

Group type: COMPARATOR
Intervention: Metoprolol 100 mg twice daily
Number of subjects: 31
Study: 7010882

Group type: EXPERIMENTAL
Intervention: Gentamicin sulfate ophthalmic solution
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chloramphenicol solution
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oxytetracycline‐polymyxin B ointment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sulphamethizole
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bacitracin‐neomycin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ristocetin‐polymyxin B solutions
Number of subjects: 60
Study: 30528516

Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery with preoperative NSAID
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional phacoemulsification
Number of subjects: 70
Study: 27696593

Group type: EXPERIMENTAL
Intervention: Inappropriate therapies (IT) in men
Number of subjects: 2510

Group type: EXPERIMENTAL
Intervention: Inappropriate therapies (IT) in women
Number of subjects: 2510

Group type: EXPERIMENTAL
Intervention: Inappropriate shock therapy
Number of subjects: 2510

Group type: EXPERIMENTAL
Intervention: Appropriate shock therapy
Number of subjects: 2510
Study: 26072346

Group type: EXPERIMENTAL
Intervention: Patching (3 hours daily for 5 months, followed by 1 month of no patching)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Observation (no treatment for 6 months)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Patching
Number of subjects: 201

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 201
Study: 23826685

Group type: EXPERIMENTAL
Intervention: Health status guided treatment algorithm based on the Clinical COPD Questionnaire (CCQ)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Usual care based on lung function
Number of subjects: 330
Study: 21868687

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Plyometrics (PLY)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no-exercise)
Number of subjects: 12
Study: 19695072

Group type: EXPERIMENTAL
Intervention: Plasma expander (hydroxyethyl starch) during surgery
Number of subjects: 74

Group type: COMPARATOR
Intervention: No plasma expander during surgery
Number of subjects: 74
Study: 17908522

Group type: EXPERIMENTAL
Intervention: Staphylococcus aureus bacteremia (SAB)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Staphylococcus aureus infective endocarditis (SAIE)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Methicillin-resistant Staphylococcus aureus (MRSA) in patients with SAB
Number of subjects: 198
Study: 15281513

Group type: EXPERIMENTAL
Intervention: IV morphine (0.125 mg/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: codeine (1 mg/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: tramadol (1.25 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo (10 mL 0.9% w/v sodium chloride)
Number of subjects: 10
Study: 11199953

Group type: EXPERIMENTAL
Intervention: amisulpride 400 mg/day (N = 12)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: olanzapine 20 mg/day (N = 13)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: sertindole 12 mg/day (N = 13)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: clozapine 100 mg/day (N = 13)
Number of subjects: 51

Group type: COMPARATOR
Intervention: healthy controls (N = 70)
Number of subjects: 51
Study: 9449585

Group type: EXPERIMENTAL
Intervention: Betanecholchloride (50 mg three times a day from the 3rd postoperative day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (received betanecholchloride only if residual urine persisted above 50 ml after the 10th postoperative day)
Number of subjects: 40
Study: 9508956

Group type: EXPERIMENTAL
Intervention: Mobile Dental System (MDS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MDS personnel
Number of subjects: 0
Study: 31776561

Group type: EXPERIMENTAL
Intervention: GHB detection in postmortem heart blood samples
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Secondary matrices analysis (peripheral blood, urine, vitreous humor, liver homogenate, brain homogenate)
Number of subjects: 348
Study: 29679748

Group type: EXPERIMENTAL
Intervention: On-site meetings
Number of subjects: 39

Group type: COMPARATOR
Intervention: Remote meetings
Number of subjects: 39
Study: 26715658

Group type: EXPERIMENTAL
Intervention: Inside brachial plexus sheath injection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Outside brachial plexus sheath injection
Number of subjects: 60
Study: 26420240

Group type: EXPERIMENTAL
Intervention: Conventional physical therapy with low-level laser therapy (protocol B)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional physical therapy (protocol A)
Number of subjects: 100
Study: 23103498

Group type: EXPERIMENTAL
Intervention: BQ-123 (endothelin type A receptor antagonist)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 21968662

Group type: EXPERIMENTAL
Intervention: Tazarotene gel (0.1%) pretreatment for one week before ALA PDT
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no pretreatment)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tazarotene gel (0.1%) pretreatment
Number of subjects: 10
Study: 18211363

Group type: EXPERIMENTAL
Intervention: Complementary foods fortified with reduced iron
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complementary foods fortified with ferrous fumarate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complementary foods fortified with reduced iron (vanilla-flavored)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complementary foods fortified with ferrous fumarate (vanilla-flavored)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sources of iron for women (reduced iron)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sources of iron for women (ferrous fumarate)
Number of subjects: 0
Study: 16492208

Group type: EXPERIMENTAL
Intervention: Vitamin C (1 g) therapy for 2 days prior to re-testing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20
Study: 12750211

Group type: EXPERIMENTAL
Intervention: New pacing technologies for heart failure; specific details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pharmacological treatment; specific details on dosage and duration not available.
Number of subjects: 0
Study: 10916529

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone, mean daily dose of 2861 micrograms/day, decreasing during treatment.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Short-term oral prednisone, mean yearly dose of 371 mg/year, decreasing during treatment.
Number of subjects: 24
Study: 8631014

Group type: EXPERIMENTAL
Intervention: High levels of alkyltransferase
Number of subjects: 167

Group type: COMPARATOR
Intervention: Low levels of alkyltransferase
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: All tumors
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Glioblastoma multiforme
Number of subjects: 167
Study: 1385069

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Octreotide (long-acting analogue of somatostatin)
Number of subjects: 0
Study: 4068043

Group type: EXPERIMENTAL
Intervention: 11-hour EMS program
Number of subjects: 34

Group type: COMPARATOR
Intervention: No-treatment control condition
Number of subjects: 34
Study: 30408106

Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best supportive care (placebo)
Number of subjects: 0
Study: 28102167

Group type: EXPERIMENTAL
Intervention: Sanatorium-based rehabilitation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Traditional rehabilitation supplemented with natural methods at a sanatorium
Number of subjects: 80

Group type: COMPARATOR
Intervention: Outpatient rehabilitation
Number of subjects: 80
Study: 23994055

Group type: EXPERIMENTAL
Intervention: Arthrocentesis as initial treatment (n = 40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conservative treatment including soft diet, physical treatment, and occlusal splint therapy (n = 40)
Number of subjects: 80
Study: 23265033

Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg/kg)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Thiopental (5 mg/kg)
Number of subjects: 82
Study: 20619238

Group type: EXPERIMENTAL
Intervention: High-dose bolus tirofiban administered prehospital
Number of subjects: 320

Group type: COMPARATOR
Intervention: High-dose bolus tirofiban administered in the catheterization laboratory
Number of subjects: 320
Study: 17916138

Group type: EXPERIMENTAL
Intervention: Azimilide 125 mg daily
Number of subjects: 482

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 482
Study: 16105524

Group type: EXPERIMENTAL
Intervention: Excision and primary closure
Number of subjects: 100

Group type: COMPARATOR
Intervention: Rhomboid excision and Limberg flap
Number of subjects: 100
Study: 11800502

Group type: EXPERIMENTAL
Intervention: Lorazepam 0.026 mg/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lorazepam 0.038 mg/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10411788

Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone agonist
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 7580831

Group type: EXPERIMENTAL
Intervention: Adjuvanted formol-inactivated interferon alpha-2a (IFN alpha)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Adjuvant alone (placebo)
Number of subjects: 12
Study: 2255521

Group type: EXPERIMENTAL
Intervention: Bicarbonate-buffered lidocaine-epinephrine-hyaluronidase
Number of subjects: 21

Group type: COMPARATOR
Intervention: Unbuffered lidocaine-epinephrine-hyaluronidase
Number of subjects: 21
Study: 7438679

Group type: EXPERIMENTAL
Intervention: Metolazone
Number of subjects: 18

Group type: COMPARATOR
Intervention: Bendroflumethiazide
Number of subjects: 18
Study: 30936377

Group type: EXPERIMENTAL
Intervention: Oncologists' estimates of expected survival time (EST)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Worst-case scenario derived from EST
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Typical scenario derived from EST
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Best-case scenario derived from EST
Number of subjects: 152
Study: 29752604

Group type: EXPERIMENTAL
Intervention: 4 mg dexamethasone submucosally
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone submucosally
Number of subjects: 45

Group type: COMPARATOR
Intervention: Normal saline submucosally (control group)
Number of subjects: 45
Study: 27430336

Group type: EXPERIMENTAL
Intervention: Combined resistance and endurance training (3x/week)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Weekly care management phone calls (CMPCs)
Number of subjects: 250
Study: 24681761

Group type: EXPERIMENTAL
Intervention: POWeR plus coaching
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: POWeR only
Number of subjects: 786

Group type: COMPARATOR
Intervention: POWeR plus coaching and POWeR only
Number of subjects: 786
Study: 22561875

Group type: EXPERIMENTAL
Intervention: Rasagiline 2 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rasagiline 1 mg/d
Number of subjects: 0
Study: 20189333

Group type: EXPERIMENTAL
Intervention: Leaflet received at home before the first visit (G1)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Leaflet received during the first visit (G2)
Number of subjects: 269

Group type: COMPARATOR
Intervention: No leaflet received (G3)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Overall absenteeism rate
Number of subjects: 269